A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer

Published:2008-02 Issue:1 Volume:13 Page:62-65
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Homesley Howard D.,Meltzer Nathan P.,Nieves Lucybeth,Vaccarello Luis,Lowendowski George S.,Elbendary Al A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-007-0731-5.pdf

Reference28 articles.

1. Homesley HD, Blessing JA, Sorosky J, et al. (2005) Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 98:294–298

2. Bonomi P, Blessing JA, Stehman FB, et al. (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3:1079–1085

3. Lhomme C, Vermorken JB, Mickiewicz E, et al. (2000) Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 36:194–199

4. Schilder RJ, Blessing JA, Morgan M, et al. (2000) Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 76:204–207

5. Ota S, Sugiyama T, Ushijima K, et al. (2001) Remission of metastatic cervical adenocarcinoma with weekly paclitaxel. Int J Gynecol Cancer 11:167–168

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies;Clinical Cancer Research;2024-03-26

2. Complete radiological response when using pembrolizumab in the mono mode in the 2nd-line drug therapy of MSI-h / dMMR-positive advanced endometrial cancer. A clinical case;Surgery and Oncology;2023-12-21

3. A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer;Gynecologic Oncology;2023-11

4. Evolution of systemic therapy for disseminated endometrial cancer: literature review;Malignant tumours;2023-06-21

5. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer;Gynecologic Oncology;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3